Citigroup raised its price target from $28.00 to $36.00 and kept its Buy rating, showing a more favorable view of Caris. The report gives no new company results, so this is an analyst opinion, not proof that the business has improved.
The higher target and retained rating show Citigroup sees stronger prospects for Caris. The report gives no new sales, profit, or other company results, so this positive read rests on the analyst's opinion.
Follow Caris Life Sciences (CAI) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for CAI